2023-506499-29-00CompletedPhase 1
A Phase 1b Study of Imvotamab in Severe Systemic Lupus Erythematosus
Source: EU CTIS (euclinicaltrials.eu) · Last updated 11 Nov 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- First submitted
- 12 Sept 2023
- Start date
- 28 Feb 2024
- Lead sponsor
- IGM Biosciences Inc.
- Diseases
- Lupus (SLE)
- EU CT number
- 2023-506499-29-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 6
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samodzielny Publiczny Zaklad Opieki Zdrowotnej Centralny Szpital Kliniczny Uniwersytetu Medycznego W Lodzi | Lodz | Poland | Completed |
| Reumed Sp. z o.o. | Lublin | Poland | Completed |
| NZOZ Lecznica MAK MED S C | Nadarzyn | Poland | Completed |
| Reumedika Sp. z o.o. | Poznan | Poland | Completed |
| Med Polonia Sp z o.o. | Poznan | Poland | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.